{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:57:24Z","timestamp":1761541044946,"version":"build-2065373602"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":4175,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1111\/j.1538-7836.2011.04334.x","type":"journal-article","created":{"date-parts":[[2011,7,29]],"date-time":"2011-07-29T06:11:54Z","timestamp":1311919914000},"page":"265-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"S1","title":["How to prevent, treat, and overcome current clinical challenges of VTE"],"prefix":"10.1016","volume":"9","author":[{"given":"J.","family":"VAN ES","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.S.","family":"EERENBERG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.W.","family":"KAMPHUISEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.R.","family":"B\u00dcLLER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0010","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","article-title":"Incidence and mortality of venous thrombosis: a population\u2010based study","volume":"5","author":"Naess","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/01.CIR.0000078468.11849.66","article-title":"The epidemiology of venous thromboembolism","volume":"107","author":"White","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0020","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(60)92299-6","article-title":"Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial","volume":"1","author":"BarrittT","year":"1960","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0025","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0030","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jama.296.8.935","article-title":"Comparison of fixed\u2010dose weight\u2010adjusted unfractionated heparin and low\u2010molecular\u2010weight heparin for acute treatment of venous thromboembolism","volume":"296","author":"Kearon","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7326\/0003-4819-140-3-200402030-00008","article-title":"Low\u2010molecular\u2010weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta\u2010analysis of randomized, controlled trials","volume":"140","author":"Quinlan","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0040","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","article-title":"Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose\u2010ranging study","volume":"6","author":"B\u00fcller","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0045","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2165\/11203710-000000000-00000","article-title":"Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis","volume":"70","author":"Hoy","year":"2010","journal-title":"Drugs"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0050","doi-asserted-by":"crossref","first-page":"287S","DOI":"10.1378\/chest.126.3_suppl.287S","article-title":"Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Levine","year":"2004","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0055","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0060","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/hrt.2004.042465","article-title":"Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non\u2010valvar atrial fibrillation: a record linkage study in a large British population","volume":"91","author":"Jones","year":"2005","journal-title":"Heart"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development","volume":"48","author":"Eriksson","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1160\/TH09-06-0361","article-title":"The clinical implications of new oral anticoagulants: will the potential advantages be achieved?","volume":"103","author":"Phillips","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0075","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1160\/TH09-07-0434","article-title":"New oral anticoagulants in development","volume":"103","author":"Weitz","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0080","doi-asserted-by":"crossref","first-page":"401S","DOI":"10.1378\/chest.126.3_suppl.401S","article-title":"Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"B\u00fcller","year":"2004","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0085","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0140-6736(98)07534-5","article-title":"Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)","volume":"353","author":"Goldhaber","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0090","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0735-1097(02)02381-1","article-title":"Thrombolytic therapy of pulmonary embolism: a meta\u2010analysis","volume":"40","author":"Thabut","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0095","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00270-007-9244-x","article-title":"The need for anticoagulation following inferior vena cava filter placement: systematic review","volume":"31","author":"Ray","year":"2008","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0100","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0105","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","article-title":"Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement","volume":"45","author":"Stangier","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0110","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE\u2010MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"Ginsberg","year":"2009","journal-title":"J Arthroplasty"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0120","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double\u2010blind, non\u2010inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0125","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1160\/TH10-10-0679","article-title":"Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE\u2010NOVATE II). A randomised, double\u2010blind, non\u2010inferiority trial","volume":"105","author":"Eriksson","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0130","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0135","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connoly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0140","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59\u20107939 \u2013 an oral, direct factor Xa inhibitor \u2013 after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0145","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0150","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short\u2010term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double\u2010blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0160","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00228-010-0889-z","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta\u2010analysis of randomized controlled trials","volume":"66","author":"Cao","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0165","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00392-010-0270-3","article-title":"Late\u2010breaking clinical trials presented at the American Heart Association Congress in Chicago 2010","volume":"100","author":"Gensch","year":"2011","journal-title":"Clin Res Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0175","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1160\/TH10-12-0808","article-title":"What do the RE\u2010LY, AVERROES and ROCKET\u2010AF trials tell us for stroke prevention in atrial fibrillation?","volume":"105","author":"Ahrens","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0180","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0185","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0190","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE\u20102): a randomised double\u2010blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0195","unstructured":"Pfizer Press Release. Bristol\u2010Myers Squibb and Pfizer initiate new study in the Apixaban phase 3 clinical trial program. 12\u20106\u20102008."},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0200","doi-asserted-by":"crossref","unstructured":"Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, et al.; AVERROES Steering Committee and Investigators. N Engl J Med. 2011; 3: 806\u201317.","DOI":"10.1056\/NEJMoa1007432"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0205","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0091270009351883","article-title":"Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers","volume":"50","author":"Ogata","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0210","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1160\/TH10-01-0066","article-title":"Randomised, parallel\u2010group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation","volume":"104","author":"Weitz","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0215","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood.V91.11.4197","article-title":"Biochemical and pharmacological properties of SANORG 34006, a potent and long\u2010acting synthetic pentasaccharide","volume":"91","author":"Herbert","year":"1998","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0220","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/j.1538-7836.2008.03089.x","article-title":"Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy","volume":"6","author":"Savi","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0225","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"B\u00fcller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0230","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1538-7836.2010.04100.x","article-title":"Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis","volume":"9","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1111\/j.1538-7836.2011.04334.x_bb0235","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1538-7836.2009.03429.x","article-title":"Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents","volume":"7","author":"Crowther","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0240","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1538-7836.2010.03759.x","article-title":"New oral antithrombotics: a need for laboratory monitoring. Against","volume":"8","author":"Bounameaux","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0245","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1538-7836.2010.03764.x","article-title":"New oral antithrombotics: a need for laboratory monitoring. For","volume":"8","author":"Mismetti","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0250","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001367.pub2","article-title":"Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism","volume":"25","author":"Hutten","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0255","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s11239-011-0562-0","article-title":"Anticoagulation in the management of venous thromboembolism in the cancer patient","volume":"31","author":"Streiff","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0260","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(03)14111-6","article-title":"Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study","volume":"362","author":"Baglin","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0265","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/CIRCULATIONAHA.109.925214","article-title":"Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model","volume":"121","author":"Eichinger","year":"2010","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0270","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1538-7836.2006.01795.x","article-title":"Post\u2010thrombotic syndrome, recurrence, and death 10\u2003years after the first episode of venous thromboembolism treated with warfarin for 6\u2003weeks or 6\u2003months","volume":"4","author":"Schulman","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0275","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archinte.160.6.769","article-title":"Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors","volume":"160","author":"Hansson","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM200107193450302","article-title":"Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators","volume":"345","author":"Agnelli","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.39098.583356.55","article-title":"Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial","volume":"334","author":"Campbell","year":"2007","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0290","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1161\/01.CIR.103.20.2453","article-title":"Comparison of 3 and 6\u2003months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12\u2003weeks of therapy after isolated calf deep vein thrombosis","volume":"103","author":"Pinede","year":"2001","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0295","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrcardio.2010.141","article-title":"Acute pulmonary embolism. Part 2: treatment","volume":"7","author":"van Es","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0300","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11239-009-0315-5","article-title":"Use of D\u2010dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow\u2010up of the PROLONG study","volume":"28","author":"Cosmi","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0305","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1503\/cmaj.080493","article-title":"Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy","volume":"179","author":"Rodger","year":"2008","journal-title":"CMAJ"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0310","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7326\/0003-4819-143-10-200511150-00006","article-title":"Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30\u2010year population\u2010based study","volume":"143","author":"Heit","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0315","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0140-6736(09)60996-X","article-title":"Pulmonary embolism in pregnancy","volume":"375","author":"Bourjeily","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0320","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/MBC.0b013e328322b429","article-title":"Comparisons of the fibrin networks during pregnancy, nonpregnancy and pregnancy during dysfibrinogenaemia using the scanning electron microscope","volume":"20","author":"Pretorius","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0325","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0741-5214(96)70010-1","article-title":"Anatomic and physiologic changes in lower extremity venous hemodynamics associated with pregnancy","volume":"24","author":"Cordts","year":"1996","journal-title":"J Vasc Surg"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0330","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-0037-1612960","volume":"87","author":"Greaves","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0335","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2007.06826.x","article-title":"The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey","volume":"139","author":"Voke","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0340","doi-asserted-by":"crossref","first-page":"627S","DOI":"10.1378\/chest.126.3_suppl.627S","article-title":"Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Bates","year":"2004","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0345","doi-asserted-by":"crossref","first-page":"340S","DOI":"10.1378\/chest.08-0677","article-title":"Treatment and prevention of heparin\u2010induced thrombocytopenia: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Warkentin","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0350","doi-asserted-by":"crossref","first-page":"844S","DOI":"10.1378\/chest.08-0761","article-title":"Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Bates","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0355","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1056\/NEJMcp031676","article-title":"Clinical practice. Treatment of deep\u2010vein thrombosis","volume":"351","author":"Bates","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0360","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jama.295.9.1050","article-title":"Management of antiphospholipid antibody syndrome: a systematic review","volume":"295","author":"Lim","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0365","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199903253401201","article-title":"A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism","volume":"340","author":"Kearon","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0370","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9343(98)00060-6","article-title":"Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group","volume":"104","author":"Schulman","year":"1998","journal-title":"Am J Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0375","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz\u2010Irastorza","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0380","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archinte.164.2.190","article-title":"Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon","volume":"164","author":"Otten","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0385","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0390","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population\u2010based case\u2013control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0395","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","article-title":"Venous thromboembolism and prognosis in cancer","volume":"125","author":"Khorana","year":"2010","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0400","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low\u2010molecular\u2010weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0405","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1038\/oby.2009.92","article-title":"Prospective study of BMI and the risk of pulmonary embolism in women","volume":"17","author":"Kabrhel","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0410","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.amjmed.2005.03.012","article-title":"Obesity as a risk factor in venous thromboembolism","volume":"118","author":"Stein","year":"2005","journal-title":"Am J Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0415","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jama.1997.03540320044033","article-title":"A prospective study of risk factors for pulmonary embolism in women","volume":"277","author":"Goldhaber","year":"1997","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0420","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/0002-9343(83)90805-7","article-title":"Risk factors for pulmonary embolism. The Framingham Study","volume":"74","author":"Goldhaber","year":"1983","journal-title":"Am J Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0425","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1538-7836.2005.01342.x","article-title":"The skinny on treatment of venous thromboembolism in obesity","volume":"3","author":"Spinler","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0430","first-page":"42","article-title":"Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low\u2010molecular\u2010 weight heparin for the treatment of venous thromboembolism","volume":"31","author":"Wilson","year":"2001","journal-title":"Haemostasis"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0435","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1055\/s-0037-1613090","article-title":"Dosing in heavy\u2010weight\/obese patients with the LMWH, tinzaparin: a pharmacodynamic study","volume":"87","author":"Hainer","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0440","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1067\/mcp.2002.127114","article-title":"The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers","volume":"72","author":"Sanderink","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0445","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.thromres.2004.10.004","article-title":"Dosage of enoxaparin among obese and renal impairment patients","volume":"116","author":"Bazinet","year":"2005","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0450","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1055\/s-0038-1653833","article-title":"Comparison of the pharmacokinetic profiles of three low molecular mass heparins \u2013 dalteparin, enoxaparin and nadroparin \u2013 administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism)","volume":"73","author":"Collignon","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0455","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.ajkd.2010.05.023","article-title":"Warfarin dosing in patients with impaired kidney function","volume":"56","author":"Limdi","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0460","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ackd.2010.06.002","article-title":"Systemic anticoagulation considerations in chronic kidney disease","volume":"17","author":"Dager","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0465","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/j.1538-7836.2009.03556.x","article-title":"Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency","volume":"7","author":"Schmid","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 2","key":"10.1111\/j.1538-7836.2011.04334.x_bb0470","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/1158586-S0-000000000-00000","article-title":"New frontiers with bemiparin: use in special populations","volume":"70","author":"Boj","year":"2010","journal-title":"Drugs"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0475","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"B\u00fcller","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2011.04334.x_bb0480","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.164.10.1077","article-title":"Subcutaneous adjusted\u2010dose unfractionated heparin vs fixed\u2010dose low\u2010molecular\u2010weight heparin in the initial treatment of venous thromboembolism","volume":"164","author":"Prandoni","year":"2004","journal-title":"Arch Intern Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2011.04334.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622055283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622055283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2011.04334.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:58:07Z","timestamp":1761533887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622055283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":95,"alternative-id":["S1538783622055283"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04334.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"type":"print","value":"1538-7836"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to prevent, treat, and overcome current clinical challenges of VTE","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04334.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}